ARWR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ARWR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Arrowhead Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $160.4 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.
Total Stockholders Equity is used to calculate Book Value per Share. Arrowhead Pharmaceuticals's Book Value per Share for the quarter that ended in Dec. 2023 was $1.49. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Arrowhead Pharmaceuticals's Debt-to-Equity for the quarter that ended in Dec. 2023 was 0.74.
The historical data trend for Arrowhead Pharmaceuticals's Total Stockholders Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arrowhead Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Sep14 | Sep15 | Sep16 | Sep17 | Sep18 | Sep19 | Sep20 | Sep21 | Sep22 | Sep23 | |||||||||||
Total Stockholders Equity | Get a 7-Day Free Trial | 244.59 | 461.78 | 408.82 | 398.52 | 271.34 |
Arrowhead Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Total Stockholders Equity | Get a 7-Day Free Trial | 377.04 | 446.77 | 364.83 | 271.34 | 160.41 |
Arrowhead Pharmaceuticals (NAS:ARWR) Total Stockholders Equity Explanation
1. Total Stockholders Equity is used to calculate Book Value per Share.
Arrowhead Pharmaceuticals's Book Value per Share for the quarter that ended in Dec. 2023 is
Book Value per Share | = | (Total Stockholders Equity | - | Preferred Stock) | / | Shares Outstanding (EOP) |
= | (160.407 | - | 0) | / | 107.5 | |
= | 1.49 |
2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.
Arrowhead Pharmaceuticals's Debt-to-Equity for the quarter that ended in Dec. 2023 is
Debt-to-Equity | = | Total Debt | / | Total Stockholders Equity | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Total Stockholders Equity | |
= | (3.421 | + | 115.157) | / | 160.407 | |
= | 0.74 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Arrowhead Pharmaceuticals's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
James C Hamilton | other: Senior Vice President | 177 EAST COLORADO BLVD, SUITE 700, PASADENA CA 91105 |
Victoria Vakiener | director | C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
Mauro Ferrari | director | 201 SOUTH LAKE AVENUE, PASADENA CA 91101 |
William D. Waddill | director | C/O CALITHERA BIOSCIENCES, 343 OYSTER POINT BLVD, SUITE 200, SO. SAN FRANCISCO CA 94080 |
Douglas B Given | director | C/O NEORX CORP, 410 WEST HARRISON ST, SEATTLE WA 98119 |
Tracie Oliver | officer: Chief Commercial Officer | 177 E COLORADO BLVD, SUITE 700, PASADENA CA 91105 |
Patrick O'brien | officer: General Counsel | 225 S. LAKE AVENUE SUITE 1050, PASADENA CA 91101 |
Martin Javier San | officer: Chief Medical Officer | 177 E COLORADO BLVD, STE 700, PASADENA CA 91105 |
Kenneth Allen Myszkowski | officer: CFO | ARROWHEAD RESEARCH CORPORATION, 201 SOUTH LAKE AVENUE, SUITE 703, PASADENA CA 91101 |
Christopher Richard Anzalone | director, officer: President and CEO | ARROWHEAD RESEARCH CORPORATION, 201 SOUTH LAKE AVENUE, SUITE 703, PASADENA CA 91101 |
Adeoye Y Olukotun | director | 3621 SOUTH STATE ST, 695 KMS PL, ANN ARBOR MI 48108 |
Backer Marianne De | director | 177 E COLORADO BLVD, SUITE 700, PASADENA CA 91105 |
Michael S Perry | director | C/O BIOTRANSPLANT INC, 196 BOSTON AVE SUITE 2800, MEDFORD MA 02155 |
James Hassard | officer: Chief Commercial Officer | 177 E COLORADO BLVD, STE 700, PASADENA CA 91105 |
Curt Bradshaw | officer: Chief Scientific Officer | 177 E COLORADO BLVD, STE 700, PASADENA CA 91105 |
From GuruFocus
By Business Wire • 12-20-2023
By Business Wire • 09-27-2023
By Business Wire • 11-29-2023
By Business Wire • 11-21-2023
By Business Wire • 06-27-2023
By GuruFocus Research • 11-23-2023
By Business Wire • 07-06-2023
By GuruFocus Research • 01-05-2024
By GuruFocus Research • 12-24-2023
By GuruFocus Research • 10-28-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.